Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Agilent Post Strong Gains in BCW Index

Qiagen and Agilent both had strong stock gains during the past week, leading the BioCommerce Week Index of multi-platform molecular biology tool firms. Qiagen shares rose 10 percent, though the reason for the upward movement is not readily apparent. Agilent's shares climbed 9.78 percent, due largely to a report in the Wall Street Journal that the firm's semiconductor business could be sold as early as late this week for as much as $2.5 billion.

Overall, the Index gained 1.16 percent for the week, trailing the Dow Jones Industrial Average, which gained 1.4 percent, the Nasdaq, which rose 3.1 percent, and the Nasdaq Biotech Index, which gained a robust 5.1 percent for the week.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(
July 12, 2005)
Last Price
(July 5, 2005)
% Change
Agilent
A
25.93
23.62
9.78
Applied Biosystems
ABI
20.26
20.31
-0.25
Beckman
BEC
64.05
64.96
-1.40
Bio-Rad
BIO
59.8
58.85
1.61
Bruker
BRKR
4.13
4.13
0.00
GE
GE
35.1
34.72
1.09
Harvard Bio
HBIO
3.28
3.18
3.14
Invitrogen
IVGN
83.88
84.9
-1.20
Molecular Devices
MDCC
20.75
21.8
-4.82
PerkinElmer
PKI
20.04
19.7
1.73
Qiagen
QGEN
13.15
11.95
10.04
Sigma
SIAL
57.49
55.99
2.68
Strategene
STGN
8.73
8.59
1.63
Thermo
TMO
27.98
26.7
4.68
Waters
WAT
38.9
38.49
1.07
Index Average
32.23
31.86
1.16
The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.